.After antibody-drug conjugate (ADC) expert Seagen was sold to Pfizer last year for a tremendous $43...
.On the heels of a phase 3 win that failed to wow capitalists, Ironwood Pharmaceuticals is back alon...
.Don't stop Monte Rosa Rehabs now. The Boston-based biotech is having a ball after signing a cope wi...
.Invite to recently's Chutes & Ladders, our summary of notable leadership hirings, shootings as w...
.Commemorating his firm's upsized going public (IPO), Septerna CEO Jeffrey Finer rang the opening be...
.AbbVie has come back to the resource of its own antipsychotic powerhouse Vraylar trying to find ano...
.GenSight Biologics is actually full weeks out of losing loan. Once more. The biotech merely has suf...
.Monopar Therapeutics is actually recovering a medication coming from the dump of AstraZeneca's unco...
.Along with new data out on Arcus Biosciences' speculative HIF-2a prevention, one group of experts e...
.After forming a genetics therapy alliance with Dyno Therapies in 2020, Roche is actually back for m...